Sulfisomidine

Summary

Sulfisomidine (CHEMBL485696) is an approved small-molecule antiinfective agent (ATC J01EB01); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01EB01
• Indications: 1 condition
• Chemistry: 278.33 Da · C12H14N4O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL485696
Name	Sulfisomidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5343
ChEBI	CHEBI:32166
ATC	J01EB01
Molecular formula	C12H14N4O2S
Molecular weight	278.33
InChIKey	YZMCKZRAOLZXAZ-UHFFFAOYSA-N

SMILES: CC1=CC(=NC(=N1)C)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-(2,6-dimethylpyrimidin-4-yl)benzenesulfonamide

ChEBI definition: A sulfonamide consisting of pyrimidine having methyl substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.

Pharmacological roles (ChEBI): antiinfective agent.

Also known as: Sulfaisodimidine, Sulfisomidina, Sulfisomidine, SULFASOMIDINE, SID144205683, SID170465986, SULFISOMIDINE, sulfisomidine

Patent coverage: 1,645 distinct patent families (4,437 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 3’,5’-cyclic-AMP phosphodiesterase 4A, Protein argonaute-2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDE4A	5.45	AC50	3585	nM	CHEMBL_ACT_25207651
AGO2	5.37	Kd	4300	nM	CHEMBL_ACT_22433327

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).